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Abstract. Proviral integration of Moloney virus 2 (PIM2) is a
pro‑survival factor of cancer cells and a possible therapeutic
target in hematological malignancies. However, the attempts
at inhibiting PIM2 have yielded underwhelming results in
early clinical trials on hematological malignancies. Recently, a
novel pan‑PIM inhibitor, JP11646, was developed. The present
study examined the utility of targeting PIM2 in multiple
solid cancers and investigated the antitumor efficacy and the
mechanisms of action of JP11646. When PIM2 expression
was compared between normal and cancer tissues in publicly
available datasets, PIM2 was found to be overexpressed in
several types of solid cancers. PIM2 ectopic overexpression
promoted tumor growth in in vivo xenograft breast cancer
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mouse models. The pan‑PIM inhibitor, JP11646, suppressed
in vitro cancer cell proliferation in a concentration‑dependent
manner in multiple types of cancers; a similar result was
observed with siRNA‑mediated PIM2 knockdown, as well as
an increased in cell apoptosis. By contrast, another pan‑PIM
inhibitor, AZD1208, suppressed the expression of downstream
PIM2 targets, but not PIM2 protein expression, corresponding
to no apoptosis induction. As a mechanism of PIM2 protein
degradation, it was found that the proteasome inhibitor, bort‑
ezomib, reversed the apoptosis induced by JP11646, suggesting
that PIM2 degradation by JP11646 is proteasome‑dependent.
JP11646 exhibited significant anticancer efficacy with minimal
toxicities at the examined doses and schedules in multiple
in vivo mice xenograft solid cancer models. On the whole,
the present study demonstrates that PIM2 promotes cancer
progression in solid tumors. JP11646 induces apoptosis at least
partly by PIM2 protein degradation and suppresses cancer
cell proliferation in vitro and in vivo. JP11646 may thus be a
possible treatment strategy for multiple types of solid cancers.
Introduction
Proviral integration of Moloney virus 2 (PIM2) belongs
to a family of serine/threonine kinases consisting of three
members: PIM1, PIM2 and PIM3 (1). PIMs are highly
conserved proteins (2), and play roles in various cellular
processes, such as cell growth, proliferation, apoptosis and
regulation of signal transduction (3). PIM2 is overexpressed
in hematopoietic cancers (3), and is considered to be an
oncogene involved in multiple signaling pathways (4). PIM2
can phosphorylate and activate substrates that control cancer
progression and tumorigenesis (4). PIM2 inhibits apoptosis
by phosphorylating downstream targets, including eukaryotic
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translation initiation factor 4E‑binding protein 1 (4EBP1),
tuberous sclerosis complex 2 (TSC2), and BCL2‑associated
agonist of cell death (BAD) (5‑8). In hematological malignan‑
cies, PIM2 promotes oncogenic progression as a pro‑survival
factor (9).
PIM2 has been demonstrated to be a possible therapeutic
target in hematological malignancies (7,10‑15), as the inhibition
of PIM2 induces apoptosis and inhibits cancer cell prolifera‑
tion in vitro and in vivo (7). Ongoing clinical trials for PIM2
inhibitors (https://clinicaltrials.gov/; Identifier: NCT01456689
and NCT01588548) (16) have yielded discouraging results
with not sufficient efficacy or dose‑limiting toxicity in hema‑
tological malignancies, and a phase 1 trial (NCT03715504)
commended in April, 2019 in solid tumors. Previous studies
reported that PIM2 also plays important roles in tumor
progression, epithelial to mesenchymal transition, chemo‑
therapy resistance (17), and aerobic glycolysis (18) in solid
tumors. However, the importance and the strategy for targeting
PIM2 in solid cancers has not been fully elucidated. Recently,
it has been shown that a novel pan‑PIM inhibitor, JP11646,
demonstrates anticancer activity in multiple myeloma (7).
The present study examined the utility of targeting PIM2 in
multiple solid cancers, and investigated the antitumor efficacy
and mechanisms of action of JP11646.
Materials and methods
Bioinformatics analysis. PIM2 expression was compared
between tumors and normal tissues in The Cancer Genome
Atlas (TCGA) dataset. Clinical and gene expression data
from RNA sequence were downloaded through the cBio‑
portal (19,20) website. The expression levels of PIMs were
compared among the cell lines using the CCLE dataset (21,22).
Cells, cell culture and reagents. Human cancer cell lines,
including pharyngeal carcinoma FaDu (HTB‑43), ovarian
cancer SK‑OV‑3 (HTB‑77), breast cancer MDA‑MB‑231
(CRM‑HTB‑26) and BT549 (HTB‑122), prostate adenocar‑
cinoma PC‑3 (CRL‑1435), liver cancer HepG2 (HB‑8065),
pancreatic ductal adenocarcinoma (PDAC) MIAPaCa‑2
(CRM‑CRL‑1420) and PANC‑1 (CRL‑1469), colorectal cancer
HT‑29 (HTB‑38) and DLD‑1 (CCL‑221), and non‑small cell
lung cancer (NSCLC) H1650 (CRL‑5883), H661 (HTB‑183),
H460 (HTB‑177) and A549 (CCL‑185) cell lines were obtained
from ATCC. The FaDu, SK‑OV‑3, MDA‑MB‑231, PC‑3,
HepG2, MIAPaCa‑2, PANC‑1 and HT29 cells were cultured
in Dulbecco's modified Eagle's medium (DMEM) (Gibco;
Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum
(FBS) (Gibco; Thermo Fisher Scientific, Inc.); the BT549,
DLD‑1, H1650, H661, H460 and A549 cells were cultured in
RPMI‑1640 (Gibco; Thermo Fisher Scientific, Inc.) with 10%
FBS in a humidified incubator at 37˚C in 5% CO2. All cell
lines were used within 20 passages after revival. All cell lines
were shown to be mycoplasma‑free using the PlasmoTest kit
(InVivoGen, Inc.). The MDA‑MB‑231 cells stably overex‑
pressing PIM2 and controls were generated by the transfection
of either 2 µg/ml PIM2‑p3xFlag‑CMV‑14, which was kindly
provided by Dr Jeremy Don (Bar‑Ilan University, Ramat Gan,
Israel) or empty vector (MilliporeSigma) using Lipofectamine
LTX (Thermo Fisher Scientific, Inc.) into MDA‑MB‑231

cells. PIM2 stably overexpressing and control clones were
selected with G418 for >2 weeks and used in further experi‑
ments. Human PIM2 specific siRNA (sense, 5'‑ACCU UC
UUCCCGACCCUCAtt‑3' and antisense, 5'‑UGAG GGUCG
GGAAGAAGGUtt‑3') or non‑targeting siRNA (#4390843,
Thermo Fisher Scientific, Inc.) was transfected into the BT549
cells at a final concentration of 30 nM using DharmaFECT 1
Transfection Agent (GE Dharmacon), according to the manu‑
facturer's instructions. The cells transfected with the siRNA
were collected at 72 h following transfection and changes in
protein expression were examined using western blot analysis.
The novel pan‑PIM inhibitor, JP11646, was obtained from
Jasco Pharmaceuticals, LLC and its structure is illustrated in
Fig. S1 (23,24). Another pan‑PIM inhibitor (AZD1208) (25)
and the proteasome inhibitor, bortezomib, were obtained from
Selleck Chemicals.
Drug sensitivity assay in in vitro. A total of 5,000 cells were
seeded per well of a 96‑well plate and incubated overnight at
37˚C. Several concentrations of JP11646, ranging from 0.005
to 10 µM, were added to each well, and the cells were incubated
for 72 h at 37˚C. Cell proliferation was measured using the
CellTiter 96® AQueous One Solution Cell Proliferation Assay
kit (Promega Corporation), according to the manufacturer's
protocol. The half‑maximal growth inhibitory (GI50) values
were calculated using non‑linear regression.
Western blot analysis. The breast cancer cell lines,
MDA‑MB‑231 and BT549, were cultured with either the vehicle
(H2O) or JP11646 (100 or 200 nM) for 24 h. The BT549 cells
were treated with 1 µM AZD1208 for 24 h. The MDA‑MB‑231
cells were pre‑treated with 1 nM Bortezomib for 12 h, and
then treated with 200 nM JP11646 for 24 h. Cells were lysed
using RIPA lysis buffer (Cell Signaling Technology, Inc.), and
lysates were quantified using the Micro BCA Protein Assay kit
(Thermo Fisher Scientific, Inc.) and equal amount of proteins
were separated by electrophoresis using 4‑12% gradient gel and
transferred to a nitrocellulose membrane. The membranes were
blocked with 5% milk for 1 h at room temperature, and then
incubated with primary antibodies (PIM1; cat. no. 3247, 1:1,000,
34, 44 kDa, PIM2; cat. no. 4730, 1:1,000, 34,38,40 kDa, PIM3;
cat. no. 4165, 1:1,000, 35 kDa, cleaved PARP; cat. no. 5625,
1:1,000, 89 kDa, 4EBP; cat. no. 9452, 1:1,000, 20 kDa,
p‑4EBPSer65; cat. no. 9451, 1:1,000, 20 kDa, TSC2; cat. no. 4308,
1:1,000, 200 kDa, or GAPDH; cat. no. 5174, 1:1,000, 37 kDa;
all from Cell Signaling Technology, Inc. and p‑TSC2Ser1798;
cat. no. sc‑293149, 1:1,000, 200 kDa from Santa Cruz
Biotechnology, Inc.) at 4˚C overnight. Bands were developed
with HRP‑labeled anti‑rabbit secondary antibodies (1:2,500;
cat. no. W4011, Promega Corporation) for 3 h at room tempera‑
ture, followed by the Clarity Western ECL detection system
(Bio‑Rad Laboratories, Inc.). Chemiluminescence signals were
acquired using a ChemiDoc MP imager (Bio‑Rad Laboratories,
Inc.).
Apoptosis assay. The breast cancer cell lines, MDA‑MB‑231
and BT549, were treated with either the vehicle (DMSO,
MilliporeSigma), JP11646 (100 or 200 nM) or AZD1208
(1 µM) for 48 h. The cells were washed with phosphate‑buff‑
ered saline (PBS) and suspended in Annexin V binding
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buffer (BioLegend, Inc.), followed by stained with Annexin
V (BioLegend, Inc.) and propidium iodide (MilliporeSigma).
The apoptotic rate was analyzed using FACS LSRFortessa
(BD Biosciences).
In vivo xenograft model. Approval from the Roswell Park
Cancer Institution Animal Care and Use Committee was
obtained for the experiments in the present study. The animals
were accommodated at a constant temperature of 22˚C and
50‑60% humidity with a 12‑h light/dark cycle, and standard
conditions with free access to food and water. A total of 114
CB17 SCID mice (female, 6‑8 weeks‑old, weighing 18‑22 g)
were purchased in‑house from the Roswell Park Comprehensive
Cancer Center. For the experiment with MDA‑MB‑231 over‑
expressing PIM2, 1x106 cell suspensions in a mixture of 2 µl
PBS and 18 µl Matrigel (Corning, Inc.) were injected into the
chest mammary fat pads and tumor growth were observed for
up to 28 days (2 groups; control and PIM2 overexpression,
n=7 mice per group). For JP11646 treatment, cell suspen‑
sions (1x106 of MDA‑MB‑231, 3x106 of MIAPaCa‑2, 2x106 of
PANC‑1, 5x106 of HepG2, 5x106 of A549, 5x106 of HT29 and
5x106 of H1650) in a mixture of 50 µl PBS and 50 µl Matrigel
were injected subcutaneously into the mouse flanks, or in the
case of MDA‑MB‑231 cells, into the abdomen mammary fat
pads. When the average tumor sizes reached 100 mm3, the
mice were randomized and treated with the vehicle, standard
care agent, or JP11646 (For MDA‑MB‑231: 2 groups; control
and JP11646, for HepG2, MIAPaCa‑2, PANC1, A549, H1650
and HT29: 3 groups; control, JP11646 and standard care agent,
n=5 per group). JP11646 was prepared fresh (2.5 mg/ml) in a
proprietary carrier solution of 30% modified β‑cyclodextrin
(Ligand Pharmaceuticals Inc.). The vehicle (proprietary carrier
solution of 30% modified β‑cyclodextrin) or 15 mg/kg JP11646
were administered by intraperitoneal injection continuously
for 2 days a week. The details of standard care agents and
the vehicles are summarized in Table SI. The control group
received two different vehicles. Tumor size and mice condi‑
tions were monitored 2‑3 times a week using calipers, and the
tumor volume was estimated using the following equation:
Volume=(length) x (width)2/2. The humanitarian endpoints
were set by the institutional IACUC, and the animals were
monitored closely by independent veterinarian technicians
who evaluated whether any endpoints had been reached. The
maximum tumor dimension was set as one of the institutional
endpoints which prevents the tumors from reaching >10% of
the animal body weight, as weighing tumors is not practical
as the experiment is proceeding. When the maximum tumor
diameter reached 2 cm (maximum observed dimension and
volume: MDA‑MB‑231, 20 mm and 3,062.5 mm 3; HepG2,
20.1 mm and 2,231.2 mm 3; MIAPaCa‑2, 20.4 mm and
3,459.6 mm 3; PANC‑1, 20.5 mm and 2,007.7 mm 3; A549,
21.6 mm and 3,179 mm3; H1650, 20.8 mm and 2,306.4 mm3;
HT29, 20.4 mm and 2,844.7 mm 3), or other humanitarian
endpoints were observed, such as weight loss (≥20%) or
tumors with ulcers, the experiment was terminated and the
animals were euthanized with CO2 inhalation (30‑70%) as per
institutional guidelines for the humanitarian care of animals
(MDA‑MB‑231, 24 days; HepG2, 23 days; MIAPaCa‑2,
29 days; PANC‑1, 40 days; A549, 29 days; H1650, 18 days;
HT29, 12 days).
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Statistical analysis. Data are presented as the mean ± standard
error of the mean. Comparisons between two groups were
performed using an unpaired Student's t‑test, and those among
more than two groups were performed using one‑way ANOVA
followed by Tukey's post hoc test. All statistical analyses were
performed using GraphPad Prism7 (GraphPad Software, Inc.).
Results
PIM2 is overexpressed in various solid cancers. It was
hypothesized that PIM2 is a factor in solid tumor progression.
Thus, TCGA datasets were interrogated to compare the PIM2
mRNA levels between cancerous and normal tissues. PIM2
was overexpressed as compared to normal tissue in several
types of solid cancers, including breast, esophageal, head and
neck, renal clear cell carcinoma, lung adenocarcinoma and
endometrial cancer (Fig. 1). On the other hand, its expression
was lower in hepatocellular carcinoma and colorectal cancer,
and the authors were not able to investigate its expression in
PDAC as there was no normal tissue mRNA expression data of
pancreatic cancer in TCGA cohort (Fig. 1). Thus, the present
study investigated whether PIM2 plays a role in tumor growth
and whether it is a potential therapeutic target in solid cancers.
PIM2 overexpression promotes tumor growth in vivo. To inves‑
tigate whether PIM2 plays a role in promoting tumor growth in
breast cancer, either empty or PIM2 inserted p3xFlag‑CMV‑14
were transfected and PIM2 overexpression was confirmed in
the MDA‑MB‑231 breast cancer cells (Fig. 2A). Control or
PIM2‑overexpressing cells were injected into mice mammary
fat pads. Tumor growth generated by PIM2‑overexpressing
cells occurred more rapidly compared with the controls
(Fig. 2B and C), suggesting that PIM2 promotes the progres‑
sion of MDA‑MB‑231 tumors.
Pan‑PIM inhibitor, JP11646, inhibits cell growth in multiple
solid cancers. Subsequently, the present study examined
whether the novel pan‑PIM inhibitor, JP11646, inhibits cell
proliferation in solid cancers. Although the GI50 values varied
among the cancer cell lines, JP11646 suppressed cancer cell
proliferation in a concentration‑dependent manner in all cell
lines tested, including in head and neck cancer FaDu, ovarian
cancer SK‑OV‑3, breast cancer MDA‑MB‑231 and BT549,
prostate cancer PC‑3, liver cancer HepG2, PDAC MIAPaCa‑2
and PANC1, colorectal cancer DLD‑1 and HT29, and NSCLC
H1650, H661, H460 and A549 cell lines (Fig. 3A and B),
although the GI50 values were not associated with PIM2 expres‑
sion (Fig. S2). Another pan‑PIM inhibitor (AZD1208) was
also tested, whose GI50 value for the acute myeloid leukemia
cell line was 0.02 µM (26). It exhibited minimal efficacy in
decreasing cell proliferation at only the highest dose of 30 µM
in both the MDA‑MB‑231 and BT549 cells (Fig. 3C).
JP11646 treatment downregulates PIM2 protein expression.
The present study then investigated the mechanisms underlying
the effects of JP11646 on cancer cell proliferation. Previous
research has demonstrated that JP11646 treatment induces the
apoptosis of multiple myeloma cells, being associated with
selective PIM2 downregulation (7), while the anti‑apoptotic
role of PIM2 is considered to be due to its phosphorylation of
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Figure 1. PIM2 expression comparison between cancerous and non‑cancerous tissues of several types of solid cancers in The Cancer Genome Atlas datasets.
T, tumor; N, normal tissue. PIM2, proviral integration of Moloney virus 2. *P<0.05, and ***P<0.001, vs. normal sample.

Figure 2. PIM2 overexpression promotes tumor growth in vivo. (A) PIM2 overexpression in MDA‑MB‑231 cells (PIM2: 34,38,40 kDa). (B) PIM2‑overexpressing
MDA‑MB‑231 cell‑derived tumor growth in an in vivo orthotopic model (n=7 mice per group). (C) PIM2‑overexpressing MDA‑MB‑231 cell‑derived tumor volume
on day 28. CTRL, empty vector transfected control; PIM2‑OE, PIM2‑overexpression; PIM2, proviral integration of Moloney virus 2. **P<0.01, vs. control
samples.

downstream targets, including 4EBP1, TSC2 and BAD (9,27).
The present study was able to recapitulate the observation that
treatment with JP11646 resulted in the selective downregulation
of PIM2, but not of PIM1 or PIM3 protein expression (Fig. 4A).
The induction of cleaved PARP by JP11646 treatment was also
confirmed in both MDA‑MB‑231 and BT549 cells (Fig. 4A),
suggesting the induction of apoptosis. To examine the effects
of PIM2 downregulation on apoptosis induction and the phos‑
phorylation of downstream targets, BT549 cells were treated
with either siRNA or the second pan‑PIM inhibitor, AZD1208.
PIM2 knockdown using siRNA also increased cleaved PARP
expression together with the decreased phosphorylation of
4EBP1 and TSC2 (Fig. 4B). In addition, the results revealed the

decreased phosphorylation of known PIM2 targets, 4EBP1 and
TSC2, at 1 µM of AZD1208, indicating the inhibition of PIM2
kinase activity (Fig. 4B). However, AZD1208 did not decrease
the PIM2 protein level and did not upregulate cleaved PARP,
likely reflecting a lack of apoptosis induction (Fig. 4B).
Proteasome‑dependent PIM2 protein degradation induces
the apoptosis of breast cancer cells. The present study further
examined the effects of targeting PIM2 on apoptosis induc‑
tion; the MDA‑MB‑231 and BT549 cells were treated with
either JP11646 or the second pan‑PIM inhibitor, AZD1208.
Consistent with the induction of cleaved PARP, JP11646 treat‑
ment significantly increased the apoptotic rate, and AZD1208
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Figure 3. The pan‑PIM inhibitor, JP11646 inhibits the proliferation of various cancer cell lines in a concentration‑dependent manner. (A) Cell viability of
JP11646 treatment for 72 h (n=12, each). (B) GI50 values of JP11646 in various solid cancer cell lines (n=12 repeats). (C) Viability of MDA‑MB‑231 and BT549
cells following AZD1208 (another pan‑PIM inhibitor) treatment for 72 h in (n=6 repeats). PIM, proviral integration of Moloney virus.

treatment did not result in a change over the baseline levels in
both MDA‑MB‑231 and BT549 (Fig. 5A‑C). The present study
then further examined the mechanisms of PIM2 downregu‑
lation by JP11646. The addition of the proteasome inhibitor,

bortezomib, with JP11646 prevented PIM2 downregulation and
decreased cleaved PARP levels, suggesting that proteasome
activity leading to PIM2 degradation is required for JP11646
to induce cell death through the apoptosis of MDA‑MB‑231
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Figure 4. JP11646 treatment downregulates the PIM2 protein level. (A) Western blot analyses of PIMs (PIM1; 34, 44 kDa, PIM2; 34,38,40 kDa, PIM3; 35 kDa)
and cleaved PARP (89 kDa) from JP11646‑treated MDA‑MB‑231 and BT549 cells. (B) Western blot analyses of PIM2, 4EBP1 (20 kDa), p‑4EBP (20 kDa),
TSC2 (200 kDa), p‑TSC2 (200 kDa) and cleaved PARP in BT549 cells transfected with siRNA or treated with AZD1208 (1 µM). PIM, proviral integration of
Moloney virus; cPARP, cleaved PARP.

cells (Fig. 5D), although it did not rescue cell viability 72 h
after treatment (Fig. S3).
PIM2 inhibition by JP11646 suppresses tumor growth in vivo.
Finally, the present study examined the efficacy of JP11646
in multiple in vivo cancer models. JP11646 significantly
suppressed tumor growth in five out of seven tested xenograft
tumor models. These included breast cancer MDA‑MB‑231,
liver cancer HepG2, PDAC MIAPaCa‑2, and NSCLCs
A549 and H1650 in vivo models (Fig. 6). However, JP11646
did not suppress tumor growth in PDAC PANC1 and colon
cancer HT29 xenograft models (Fig. 6). Standard therapeutic
agents were used for some models for the relative measure of
JP11646 efficacy, sorafenib for liver cancer, gemcitabine for
PDAC, paclitaxel for NSCLC and irinotecan for colorectal
cancer. JP11646 resulted in comparable or improved antitumor
efficacy when compared to most standard therapies. At the
administered drug doses and schedules, no mouse exhibited
a weight loss >20% or any other detectable severe side‑effect.
Discussion
In the present study, it was demonstrated that PIM2 promoted
in vivo tumor growth and may thus represent a potential thera‑
peutic target. Targeting PIM2 using siRNA or the pan‑PIM
inhibitor, JP11646, resulted in the downregulation of PIM2 and
the upregulation of cleaved PARP expression in breast cancer
cells. JP11646‑induced PIM2 degradation and the induction
of apoptosis were dependent on proteasome activity and were
associated with the inhibition of cancer cell proliferation
in vitro and tumor growth in vivo.
Consistent with previous findings (7), the present study
demonstrated that PIM2 downregulation induced apoptosis.

The findings suggested that treatment with JP11646 resulted
in a more profound inhibition of PIM2 signaling. It was found
that the effect of JP11646 on PIM2 was proteosome‑dependent
in MDA‑MB‑231 cells. A previous study demonstrated the
possibility of kinase‑independent PIM2 activity (7), which may
explain the enhanced anticancer efficacy of JP11646 as compared
to other kinase inhibitors. Although bortezomib did not rescue
cell viability at 72 h after treatment, the mechanisms through
which JP11464 leads to cell death are not yet fully understood.
This mechanism of JP11646 which leads to apoptosis by prote‑
asome‑dependent PIM2 protein degradation warrants further
investigation in multiple cancer types in the future. It may lead
to improvements in clinical efficacy, which have not yet been
achieved by the current clinical testing of PIM inhibitors (16).
The present study also demonstrated the efficacy of
JP11646 in preclinical mouse models of multiple solid cancers.
As previously reported, it is necessary to demonstrate an effi‑
cacy in in vivo preclinical models before translating this into
clinical practice (28‑30). The present study broadly examined
the efficacy of JP11646 in variety of cancers independent of
PIM2 expression based on the hypothesis that targeting PIM2
for degradation highlights a potential novel mechanism. In
total, five out of seven JP11646‑treated cancers exhibited a
significant tumor growth suppression compared to the controls
with acceptable side‑effect profiles. These results were
compared to standard‑of‑care treatments with comparable
results. This suggests that targeting PIM2 by JP11646 may be
a potential novel therapeutic strategy for the treatment of solid
cancers.
Even though the current experimental results demonstrated
the anticancer efficacy of JP11646 in multiple cancers, JP11646
efficacy was not associated with PIM2 mRNA expression.
This could be due to differences in mRNA translation,
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Figure 5. Proteasome‑dependent PIM2 downregulation induces apoptosis. Apoptosis assay of (A) MDA‑MB‑231 and (B) BT549 cells treated with JP11646
(100 nM, 200 nM) or AZD1208 (1 µM). (C) Apoptotic cell rate comparison of MDA‑MB‑231 and BT549 cells. (D) Western blot analyses of PIM2 (34, 38 and
40 kDa) and cleaved PARP (89 kDa) in MDA‑MB‑231 cells treated with JP11646 (200 nM) and/or bortezomib (1 nM). PIM2, proviral integration of Moloney
virus 2; cPARP, cleaved PARP. *P<0.05 and **P<0.01, vs. control samples.

the dependence of cells on PIM2 signaling or another yet
undiscovered function of PIM2 protein. It may also be due to
differences in PIM2 targeting for degradation or the existence
of compensatory signaling pathways. The off‑target effects
of JP11646 have been extensively investigated (7). Although
a previous study reported the specificity of PIM2 inhibition
by JP11646 (7), there is a possibility that the response to
JP11646 is more complex, as PIM2 signaling has been shown
to be involved in numerous important pathways in cancer
cell biology. Furthermore, JP11646 did not exhibit efficacy in
some mouse models. The resistance mechanisms to JP11646
are under investigation. One possibility of resistance is the
crosstalk between cancer cells and the tumor microenviron‑
ment. Although the present study used immune deficient
mice, there are multiple components other than immune cells.
The tumor microenvironment plays a role to support tumor
progression (31); therefore, it may help cancer cells to acquire
resistance. It may lead to the inability of JP11646 to achieve a
necessary concentration intracellularly due to restricted diffu‑
sion or efflux pumps. Further studies are thus warranted to
identify predictive markers of JP11646 sensitivity.

The present study demonstrated anticancer effects by
targeting PIM2. However, the detailed mechanisms of PIM2
function and necessary inhibition have not yet been fully
elucidated. The molecular mechanisms of PIM2 function and
the effect of the JP11646 inhibitor in multiple cancer types,
as well as the efficacy of other PIM2 inhibitors needs to be
investigated in the future. Further studies are warranted to fill
this gap in knowledge.
In conclusion, the present study found that PIM2 promoted
cancer progression in solid tumors. PIM2 inhibition by
JP11646 induced apoptosis via PIM2 protein degradation and
suppressed cancer cell proliferation in vitro and in vivo. PIM2,
if properly targeted, may serve as a novel therapeutic target for
the treatment of solid cancers.
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